Review
Nature Reviews Cancer 7, 925-936 (December 2007) | doi:10.1038/nrc2251
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Laurent Antoni1,3, Nayanta Sodha3,2, Ian Collins1 & Michelle D. Garrett1 About the authors
Abstract
In the past decade, CHK2 has emerged as an important multifunctional player in the DNA-damage response signalling pathway. Parallel studies of the human CHEK2 gene have also highlighted its role as a candidate multiorgan tumour susceptibility gene rather than a highly penetrant predisposition gene for Li–Fraumeni syndrome. As discussed here, our current understanding of CHK2 function in tumour cells, in both a biological and genetic context, suggests that targeted modulation of the active kinase or exploitation of its loss in tumours could prove to be effective anti-cancer strategies.
- View At a Glance
Author affiliations
- Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
- Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.
- These authors contributed equally to this work.
Correspondence to: Michelle D. Garrett1 Email: michelle.garrett@icr.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A sense-abl response?Nature News and Views (01 May 1997)
A sense-abl response?Nature News and Views (29 May 1997)
See all 3 matches for News And ViewsRESEARCH
Effects of spider Macrothele raven venom on cell proliferation and cytotoxicity in HeLa cellsActa Pharmacologica Sinica Original Article
PD-L2 is a second ligand for PD-1 and inhibits T cell activationNature Immunology Article (01 Mar 2001)
See all 31 matches for Research